Autologous Dendritic Cell–Tumor Antigen Vaccine Shows Clinical Benefit in Glioblastoma
A vaccine consisting of autologous dendritic cells exposed to tumor antigens was well tolerated and showed clinical benefit among patients with glioblastoma.
Diagnosis & Disease Information
Pseudoprogression With Immunotherapy in Cervical Cancer
A study evaluated characteristics of pseudoprogression among patients with cervical cancer treated with ICIs.
Neoantigen Vaccine Labeled “Well Tolerated” in Adjuvant Setting
A neoantigen vaccine administered in the adjuvant setting to patients with different cancer types was well tolerated and generated a T-cell response .
Dexamethasone May Shorten Survival in Patients With Glioblastoma Treated With ICIs
Use of dexamethasone was associated with shorter survival in those with glioblastoma treated with a PD-1/PD-L1 inhibitor.
BEMPEG Plus Nivolumab Induces Durable Responses in Metastatic Melanoma
BEMPEG combined with nivolumab resulted in deep and durable responses among patients with treatment-naive metastatic melanoma, according to phase 2 data.
IL-15/ IL-15Rα Heterodimer Shows Antitumor Activity With Spartalizumab in Pretreated Advanced Cancers
NIZ985, a heterodimer of IL-15 and IL-15α, showed antitumor activity when combined with spartalizumab among patients with pretreated, advanced solid tumors, in a phase 1 study.
Enhancing Antigen Presentation With NKTR-262 Shows Early Efficacy in Phase 1 Trial
NKTR-262 enhances antigen presentation and demonstrated early efficacy and a tolerable safety profile in combination with bempegaldesleukin in pretreated advanced solid tumors.
AXL Inhibitor Plus Pembrolizumab Shows Activity in Previously Treated NSCLC
Bemcentinib, an AXL inhibitor, was tolerable and demonstrated antitumor activity in combination with pembrolizumab in AXL-positive, relapsed NSCLC.
- Loading...
Loading...
Next post in SITC 2020
Loading... 
Loading...